REGULATORY

MHLW Details New Operational Rules for Conditional Approvals from May

March 3, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Ministry of Health, Labor and Welfare (MHLW) has issued new guidance on how the country’s conditional approval system for pharmaceuticals will be operated under the revised Pharmaceuticals and Medical Devices (PMD) Act, which takes effect in May. In a…

To read the full story

MHLW Issues Q&A on Conditional Approval System
May 1, 2026
MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026

REGULATORY

MHLW Issues Q&A on Conditional Approval System
May 1, 2026
Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…